At AboGen, we believe that drawing large volumes of blood using invasive needles for research and diagnostic purposes does not fit with the 21st century.
Founded in 2012, AboGen Inc. is the world's first company to show, through various independent 3rd party validators, that its technology can allow for the use of saliva, instead of blood, for various cell based research and diagnostic applications, including serological and genetic.
We do not plan on replacing blood completely but we do plan on elevating saliva, as an alternative to blood for various cell based diagnostic applications, ABOve and beyond GENetic applications.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 474 Congress St., Portland,me 04101,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- abogen.com
- Keywords
- Epigenetics, Biotechnology, Diagnostics.
- HQ
- Portland, ME
Abogen, Inc. Questions
Abogen, Inc.'s website is abogen.com
Abogen, Inc.'s LinkedIn profile is https://www.linkedin.com/company/abogen
Abogen, Inc. has
3 employees.
View email and phone details for 3
employees at Abogen, Inc..
Abogen, Inc.'s industry is
Biotechnology Research
Abogen, Inc.'s top competitors are
Eikon Therapeutics,
Borealis Biosciences, Inc.,
Versant Ventures,
Cambrian Bio,
Mammoth Biosciences,
Orna Therapeutics,
Kallyope,
Insitro,
Abogen Biosciences,
Tessera Therapeutics.
Abogen, Inc.'s categories are Biotechnology Research
Abogen, Inc.'s founding year is 2012
